Saluda Medical: revenue up 26% as US implants hit a record 838
Saluda Medical reported Q1 FY27 revenue of US$23.1m, up 26%, with US implants up 55% to 838 and FY27 guidance reaffirmed, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Saluda Medical's revenue in the first quarter of fiscal 2027 rose 26% year on year to US$23.1m. US implants climbed 55% to a record 838.
The company reaffirmed its guidance for the full fiscal year. Growth is supported by the commercialization of CAP24 and expansion into new territories and sales channels. Cash use was elevated by concentrated one-time payments, and the estimated runway extends to about June 2027.
why it matters
For the broader market this is a small medtech company's report, so the impact on major indices is limited. Investors will focus mainly on implant trends and the pace of cash burn, and the funding runway to June 2027 keeps future capital raising in view.
tags
instruments
sources
- Saluda Medical: Revenue grew 26% as US implants surged 55%; FY27 guidance was reaffirmed — TradingView, 28 October 2026 at 22:44 UTC
- Saluda Medical: Revenue grew 26% and US implants hit a record as FY27 guidance held — TradingView, 28 October 2026 at 22:44 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗